antibodies

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

News

Chai raises $130m for AI drug discovery platform

AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.

News

Epsilogen buys rival cancer antibody firm TigaTx

Epsilogen has bought TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies.

News

Roche taps Oxford BioTherapeutics for cancer drug discovery

Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

News

J&J abandons work with Genmab on Darzalex successor

Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.

News

AMD shadows NVIDIA with a move into AI drug discovery

Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.

Welsh firm Antiverse raises funds for AI antibody platform

Chai raises $130m for AI drug discovery platform

Epsilogen buys rival cancer antibody firm TigaTx

Roche taps Oxford BioTherapeutics for cancer drug discovery

J&J abandons work with Genmab on Darzalex successor

AMD shadows NVIDIA with a move into AI drug discovery

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

antibodies

Editor's Picks